Navigation Links
PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies
Date:2/24/2009

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride manufactured under cGMP for use in clinical and commercial drug products developed with PDS Biotechnology's Versamune(TM) nanoparticle technology. PDS Biotechnology will own the intellectual property rights to products incorporating the chiral DOTAP lipids for immunotherapeutic applications.

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology has been awarded grants by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-HPV and Versamune(TM)-Melanoma. Versamune(TM)-Melanoma is being developed to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system. Simultaneously it acts as a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

Merck Eprova AG (www.merckeprova.com), located in Schaffhausen, Switzerland, is a wholly owned subsidiary of Merck KGaA located in Darmstadt, Germany. Merck Eprova AG specializes in the development and production of cGMP grade, highly purified and characterized Drug Delivery Compounds such as cationic lipids, PEGs, PEG-lipids, and phospholipids. In addition Merck Eprova AG is a centre of excellence for reduced folates in the pharmaceutical and nutritional field and the world's leading supplier of reduced folates.


'/>"/>
SOURCE PDS Biotechnology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
2. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
3. Yongye Biotechnology International to Expand its Network of Branded Stores
4. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
5. Yongye Biotechnology to Present at Roth Conference
6. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
7. Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
10. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
11. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DIEGO , March 29, 2017  Halozyme ... novel oncology and drug-delivery therapies, today announced that ... Food and Drug Administration voted 11 to 0 ... the skin) injection was favorable for patients in ... B-cell lymphoma and chronic lymphocytic leukemia. The FDA ...
(Date:3/29/2017)... ... 29, 2017 , ... Bactana Animal Health, a company developing natural products aimed ... enhancement of the gut microbiota, today announced the closing of its first round of ... Sustainable Income Capital Management, LLC and a number of private investors. The company will ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or ... a new risk stratification test for breast cancer, via its ... Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with a ... for developing breast cancer.   ... BreastSentry measures the fasting plasma levels ...
(Date:3/28/2017)... Hong Kong (PRWEB) , ... March 28, 2017 ... ... has selected NetDimensions Learning to replace paper-based processes and enhance training plan management ... “We are very pleased to partner with the SHL Group to help improve ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):